Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. (2021)
Attributed to:
King's Health Partners Confidence in Concept
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1136/gutjnl-2021-324388
PubMed Identifier: 33753421
Publication URI: http://europepmc.org/abstract/MED/33753421
Type: Journal Article/Review
Volume: 70
Parent Publication: Gut
Issue: 5
ISSN: 0017-5749